Dr. Lionel Galibert has accumulated over 15 years of experience in the adeno-associated virus (AAV) gene therapy field. On the team of Dr. Otto Wilhelm Merten in Genethon, France, he helped develop a single baculovirus to produce rAAV8 in Sf9 cells, as well as demonstrated the involvement of the baculovirus protease on the degradation of certain AAV capsids. Dr. Galibert then worked within Dr. Michael Linden's group at Pfizer in London, and was involved in the development of the rAAV production system in fixed-bed bioreactors using mammalian cells. For the last 4 years, Dr. Galibert worked in Kuopio's biotech environment with positions in FinVector and its sister company Kuopio Center for Gene and Cell therapy. Now working in Dr. Kari Airenne's group, he leads their AAV research with a particular focus on the wild-type AAV. He will be presenting the work they performed on the novel AAV protein “Membrane-Associated Accessory Protein” MAAP.